Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE), Allogene Therapeutics (ALLO) and Boston Scientific (BSX) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Belite Bio, Inc. ADR (BLTE)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR, with a price target of $200.00. The company’s shares closed last Friday at $172.76.
According to TipRanks.com, Chen is a 1-star analyst with an average return of
Currently, the analyst consensus on Belite Bio, Inc. ADR is a Strong Buy with an average price target of $215.29.
See the top stocks recommended by analysts >>
Allogene Therapeutics (ALLO)
In a report issued on April 9, Samantha Semenkow from Citi assigned a Buy rating to Allogene Therapeutics, with a price target of $4.00. The company’s shares closed last Friday at $2.72.
According to TipRanks.com, Semenkow is a 2-star analyst with an average return of
Currently, the analyst consensus on Allogene Therapeutics is a Strong Buy with an average price target of $8.67, which is a 193.9% upside from current levels. In a report issued on March 31, TD Cowen also reiterated a Buy rating on the stock.
Boston Scientific (BSX)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific today and set a price target of $105.00. The company’s shares closed last Friday at $61.79.
According to TipRanks.com, Steed is a 3-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $102.14, which is a 66.0% upside from current levels. In a report issued on March 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $90.00 price target.
Read More on BLTE:
Disclaimer & DisclosureReport an Issue
- Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
- Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
- Belite Bio Eyes 2027 Launch After Pivotal Win
- Belite Bio price target raised to $200 from $185 at H.C. Wainwright
- Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
